Reviews/Anti CGRP Antibodies/Galcanezumab for episodic cluster headache
Cluster Headache · CGRP-CH-01 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
The question is whether galcanezumab stops episodic cluster headache attacks. One dedicated randomised trial [5] directly tested this and found the drug cut attacks more than a dummy injection over the first three weeks, and two separate real-world patient groups [20][25] saw similarly large drops. But that one trial was stopped early with fewer patients than planned, and its result only just cleared the bar for statistical significance. The real-world studies had no comparison group, which matters because cluster headache bouts tend to fade on their own, so some of the improvement may not be the drug. A companion trial in the chronic form of the disease [10] showed no benefit at all. The panel judged the evidence points the right way and is backed up, but rests on thin foundations, which is why it sits at the cautious end rather than being called settled.
A dedicated phase-3 RCT in episodic cluster headache [5] found galcanezumab 300 mg reduced weekly attacks by 8.7 versus 5.2 for placebo (difference, 3.5 attacks per week; 95% confidence interval, 0.2 to 6.7; P = 0.04), with 71% versus 53% achieving at least 50% reduction at week 3. Two uncontrolled real-world cohorts corroborate this direction: [20] reports mean daily attacks falling from 2.6 to 1.2 in episodic patients (p < 0.001), and [25] reports 78.8% achieving at least 50% weekly reduction at week 3. The companion chronic cluster headache RCT [10] did not meet its primary endpoint (-5.4 galcanezumab vs -4.6 placebo, p = 0.334). The effect is thus confined in this corpus to the episodic population and to a single controlled study. The contested point: The division is whether a single underpowered trial [5] with a marginal P = 0.04 and a 95% confidence interval reaching down to 0.2, supported only by uncontrolled cohorts [20][25] against a spontaneously-remitting condition, is a strong enough basis for the word 'prevents'. The negative chronic-CH trial [10] further splits the picture on how far the preventive effect generalises.
All 38 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Anti CGRP Antibodies, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The pivotal RCT [5] was halted before reaching its planned sample of 162 (only 106 enrolled), is underpowered, and its primary result is marginal (P=0.04) with a 95% CI (0.2 to 6.7) whose lower bound nearly touches zero — a fragile basis for the strong verb 'prevents'.
The supporting studies [20] and [25] are uncontrolled single-arm cohorts. Episodic cluster headache bouts remit spontaneously, so 3-4 week attack reductions are confounded by natural bout resolution rather than drug effect — a serious indirectness/confounding threat for a prevention claim.
Where it remains uncertain. The trial [5] was halted at 106 of a planned 162 patients with a marginal result, its supporting cohorts [20][25] are uncontrolled against a remitting condition, and the chronic-CH trial [10] was negative.
Aleatory
The pivotal trial [5] enrolled only 106 of a planned 162 patients, so random variation has a large influence on the estimated effect.
Epistemic
The RCT [5] measured only weeks 1 through 3; no corpus study establishes whether prevention is sustained beyond that window.
Inferential
Inferring a preventive drug effect from single-arm cohorts [20][25] against a remitting condition requires an assumption the data cannot support.
The load-bearing papers from a corpus of 38, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary RCT evidence that galcanezumab reduces episodic cluster headache attack frequency versus placebo; the direct test of the claim.
“The mean reduction in the weekly frequency of cluster headache attacks across weeks 1 through 3 was 8.7 attacks in the galcanezumab group, as compared with 5.2 in the placebo group (difference, 3.5 attacks per week; 95% confidence interval, 0.2 to 6.7; P = 0.04).”
Panel auditInternal validity: medium · scope of inference: Galcanezumab 300 mg for episodic cluster headache attack prevention over weeks 1-3 after first dose.Key limitations: underpowered, halted recruitment · short assessment window · CI lower bound near zero
Negative chronic cluster headache RCT that bounds the claim to episodic disease and warns against generalising the preventive effect.
“The primary endpoint was not met; mean change in weekly attack frequency was -4.6 placebo versus -5.4 galcanezumab ( p = 0.334).”
Panel auditInternal validity: high · scope of inference: Galcanezumab 300 mg for chronic (not episodic) cluster headache prevention.Key limitations: chronic not episodic subtype
Independent real-world cohort corroborating attack-frequency reduction in episodic cluster headache.
“At week 4, mean daily attacks decreased from 2.6 to 1.2 in eCH ( p < 0.001) and from 2.8 to 1.5 in cCH ( p = 0.004) with significant effect sizes.”
Panel auditInternal validity: low · scope of inference: Galcanezumab 240 mg attack reduction in episodic cluster headache at 4 weeks in routine practice.Key limitations: no control arm · small n · 4-week follow-up
3 of 38 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
One direct positive RCT plus two corroborating real-world eCH cohorts support the claim, but the trial's marginal power and the uncontrolled nature of the supporting data keep confidence at the lower edge of Likely rather than Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No confirmatory episodic RCT. The claim rests on one underpowered, marginally significant trial [5]; replication is absent. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A second adequately powered, placebo-controlled RCT in episodic cluster headache enrolling the full planned sample.
Open question: Is the preventive effect of galcanezumab in episodic cluster headache reproducible in a second, adequately powered RCT? Why it is still open: The only controlled evidence [5] was halted at 106 of a planned 162 patients with a marginal P = 0.04 and a confidence interval reaching 0.2.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19